Creating Efficiencies in Drug Discovery and Development Using Artificial Intelligence

Priya Mannan, Associate General Counsel, Novartis Institutes for Biomedical Research, USA

The recent growth of machine learning applications using artificial intelligence (AI), ranging from drug discovery to improvements in patient care, has coincided with increased investments from pharmaceutical and technology companies. Subsequently, there has been a sharp increase in the number of start-ups in this space along with heightened expectations regarding the implications of AI in the health care industry. Given the strict regulations pertaining to drug development and commercial marketing, there are questions as to whether AI can operate within the contours of existing laws or would require novel legal frameworks. This article makes an effort to address those emerging questions.

Read full paper Subscribe to the IICJ
USA Artificial Intelligence Pharmaceutical August 2018 Vol.11, No. 44, Summer 2018

Priya Mannan

More

Haripriya M. Mannan, Associate General Counsel, NIBRI, Cambridge, MA Priya joined Novartis in June 2009 as Associate General Counsel for the Novartis Institutes of Bio Medical Research, Inc. (“NIBR”) in Cambridge, MA. At NIBR, she is the Global Head of Compliance and manages social media, e-commerce, Big data, clinical, ethical, privacy and regulatory matters. Prior to joining NIBR, Priya was a Senior Counsel At Baxter International Inc., in Deerfield, IL. At Baxter, Priya was an FDA Regulatory and Healthcare Compliance attorney and also managed clinical trials and product promotion for the Bioscience business for the company. Priya’s first in-house position was at Pfizer Inc., where she managed in-licensing of phase II and III compounds followed by Medtronic Inc., where she was responsible for clinical, research & development, regulatory and general legal business transactions. Before joining as in-house counsel, Priya was associated with the firms of Reid & Riege and Cantor Colburn based in Hartford, CT where she practiced Healthcare law. She received her undergraduate degree from Madras University majoring in Bio Chemistry and Chemistry and her first law degree also from Madras University. She also received her JD and LLM degrees from St. Louis University School of Law, St. Louis. Missouri.

Novartis Institutes for Biomedical Research

More

The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

USA Artificial Intelligence Pharmaceutical August 2018 Vol.11, No. 44, Summer 2018